DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0037355A1 Kirn Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0037355A1 Kirn Et Al US 2015 0037355A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0037355A1 Kirn et al. (43) Pub. Date: Feb. 5, 2015 (54) GENERATION OF ANTIBODIES TO TUMOR A 6LX39/235 (2006.01) ANTIGENS AND GENERATION OF TUMIOR A6135/26 (2006.01) SPECIFIC COMPLEMENT DEPENDENT GOIN33/574 (2006.01) CYTOTOXCITY BY ADMINISTRATION OF C07K 6/8 (2006.01) ONCOLYTIC VACCNAVIRUS A6II 45/06 (2006.01) CI2N 7/00 (2006.01) (75) Inventors: David Kirn, Mill Valley, CA (US); John A 6LX39/395 (2006.01) Bell, Ottawa (CA); Caroline Breitback, (52) U.S. Cl. San Francisco, CA (US); Anne Moon, CPC ............. A6IK39/285 (2013.01); A61K.39/395 San Francisco, CA (US); Tae-Ho (2013.01); A61 K39/12 (2013.01); A61 K Hwang, Busan (KR); Yu Kyoung Lee, 39/145 (2013.01); A61K 39/165 (2013.01); Busan (KR); Mi-kyung Kim, Busan A61K39/17 (2013.01); A61 K39/125 (KR) (2013.01); A61K 39/205 (2013.01); A61 K 39/245 (2013.01); A6IK 39/235 (2013.01); (73) Assignees: SILLAJEN, INC., Busan (KR): A6135/26 (2013.01); GOIN33/574 JENNEREX INC., SAN FRANCISCO, (2013.01); C07K 16/18 (2013.01); A61K 45/06 CA (US) (2013.01); C12N 7/00 (2013.01); C12N 2710/10034 (2013.01); C12N 27.10/16634 (21) Appl. No.: 13/978,113 (2013.01); C12N 27.10/24034 (2013.01); C12N 2760/18734 (2013.01); C12N 2760/18434 (22) PCT Fled: Jan. 4, 2012 (2013.01); C12N 2760/18134 (2013.01); C12N PCT NO.: PCT/US12/20173 2760/20034 (2013.01);s C12N 2760/16034 (86) O (2013.01); C12N 2770/36034 (2013.01); C12N S371 (c)(1), 2770/32034 (2013.01); C12N 2770/32334 (2), (4) Date: Oct. 24, 2014 (2013.01); C12N 2750/14034 (2013.01); A61 K 2039/507 (2013.01) Related U.S. Application Data USPC .................. 424/174.1; 424/204.1; 424/209.1; (60) Provisional application No. 61/429,622, filed on Jan. 424/212.1; 424/214.1; 424/216.1; 424/218.1; 4, 2011. 424/224.1; 424/230.1; 424/231.1; 424/232.1; s 424/233.1; 424/93.71; 435/375:506/9; Publication Classification 5307389.7 (51) Int. C. (57) ABSTRACT A 6LX39/285 (2006.01) The present invention relates to methods and compositions A6 IK 39/2 (2006.01) for use in inducing tumor-specific antibody mediated A6 IK39/45 (2006.01) complement-dependent cytotoxic response in an animal hav A6 IK39/65 (2006.01) ing a tumor comprising administering to said animal a com A 6LX39/7 (2006.01) position comprising a replication competent oncolytic virus A 6LX39/25 (2006.01) wherein administration of the composition induces in the A 6LX39/205 (2006.01) animal production of antibodies that mediate a CDC response A6 IK 39/245 (2006.01) specific to said tumor. Patent Application Publication Feb. 5, 2015 Sheet 1 of 26 US 2015/0037355A1 FIGURE 1A m Sessi 'sy X-53s reise $3888 assi: Sssssss for SS is scis WX $3e3i's assist Sessis iss's X-S8s res:Še XX 88s: six Š S& Rai SC Patent Application Publication Feb. 5, 2015 Sheet 2 of 26 US 2015/0037355A1 FIGURE 1B s S 3. 3S 3. says post irection Patent Application Publication Feb. 5, 2015 Sheet 3 of 26 US 2015/0037355A1 FIGURE 1C 2 won S is ciersy mcame is is sessity is . .8. 8 is . 8 Seri case is Patent Application Publication Feb. 5, 2015 Sheet 4 of 26 US 2015/0037355A1 FIGURE 1D D VX2 lysates PBMC lysates 2 Nave at Sei 2. 3W post JX-594 into VX2 bearing rabbit Patent Application Publication Feb. 5, 2015 Sheet 5 of 26 US 2015/0037355A1 FIGURE 2A - FIGURE 2B s S & s ex & 's s 3. Patent Application Publication Feb. 5, 2015 Sheet 6 of 26 US 2015/0037355A1 FIGURE 3A swsS. S is 888& $$$$$. : - S : is sexists: $88: is $88ws $88.8 xxi.88. Patent Application Publication Feb. 5, 2015 Sheet 7 of 26 US 2015/0037355A1 FIGURE 3B 3 is $8'3: x set 38: S: s s **** 2º:32.§ c.k& Patent Application Publication Feb. 5, 2015 Sheet 8 of 26 US 2015/0037355A1 FIGURE 3C "b" serum "c" serum d" serum Patent Application Publication Feb. 5, 2015 Sheet 9 of 26 US 2015/0037355A1 FIGURE 3D 2O O 8 O 8 O 4. O 2 O O 5 O 3O Time of Heat Treatment (Min at 56 °C) Patent Application Publication Feb. 5, 2015 Sheet 10 of 26 US 2015/0037355A1 FIGURE 4A #301-RCC pt. SSSSSSSSS Patent Application Publication Feb. 5, 2015 Sheet 11 of 26 US 2015/0037355A1 FIGURE 4B #304 --melanoma pt. m g s: 5 s E wy & { ge is is is 120 y SS. m19 in &e (y s 100 S Š 80 60 40 s Patent Application Publication Feb. 5, 2015 Sheet 12 of 26 US 2015/0037355A1 FIGURE 4C if 2. HCC pt, S &SS Patent Application Publication Feb. 5, 2015 Sheet 13 of 26 US 2015/0037355A1 FIGURE 4D Patent Application Publication Feb. 5, 2015 Sheet 14 of 26 US 2015/0037355A1 FIGURE 5A i8.8s2 i S. s A2780 cell viability (CDC activity) is of JX-39s injected sets baseine serin Patent Application Publication Feb. 5, 2015 Sheet 15 of 26 US 2015/0037355A1 FIGURE 5B 100 - Heps2HeroG2 B SS JNU449 8. N “res s is SNU475 s: SNU739. x i ( 20 S 3 SS is is 8. 8.S 7 Post X-584 injection Days Patent Application Publication Feb. 5, 2015 Sheet 16 of 26 US 2015/0037355A1 FIGURE 5C C 5 ( 5 O S 3 35 it 5 is 55 S 65 Post JX-594 injection Days) Patent Application Publication Feb. 5, 2015 Sheet 17 of 26 US 2015/0037355A1 FIGURE 5D SNU475 x N. Y. 8 8, 5 O 5 25 3. 35 is 45. 5. 55 SO 85 7. Post JX-584 injection (Days Patent Application Publication Feb. 5, 2015 Sheet 18 of 26 US 2015/0037355A1 FIGURE 5E - was 2-&s^ ^ y SNU449 m &^. ai, . 25 3. 35 is is 55 3 SS Post JX-594 injection (Days) Patent Application Publication Feb. 5, 2015 Sheet 19 of 26 US 2015/0037355A1 FIGURE 6 S Patent Application Publication Feb. 5, 2015 Sheet 20 of 26 US 2015/0037355A1 FIGURE 7A -O JX-594 naive Serum -O- JX-594 injected serum O.O O.2 O.4 Sunitinib dose (ug/mL) Patent Application Publication Feb. 5, 2015 Sheet 21 of 26 US 2015/0037355A1 FIGURE 7B 120 6 O 40 -O- JX-594 injected Serum 2O al-O JX-594 naive Serum O.O O.5 1.O 15 2.O Sorafenib dose (ug/mL) Patent Application Publication Feb. 5, 2015 Sheet 22 of 26 US 2015/0037355A1 FIGURE 7C --a && S&S$388 & S&isiy Patent Application Publication Feb. 5, 2015 Sheet 23 of 26 US 2015/0037355A1 FIGURE 8 CDC profile after JX-594 ..a a. treatment in CC patients. Red colored serum (six patients) were pooled for SEREX screening is is R$ 3: 3& S. 38 is S as S Post X-SS: isjeciati jays wwy sts as st cs: ines - artial caNA phage librar E.gif ytic infection, &age; it assifer to serixate & Essay scsesitg with pixie Sier8 &ciexi settish : sesses&e exi ser:Y is it. ge3: & 33six & & {x&iss aftes 2 xis: y scissisi'g. is $38ises 38&ia &Sig's Cississ so sistig sig &38 S33& &ise $38,383 & 888 pityay streeting, Ess&ix spie is post 38 Sgiates x 3 sti&stigs Eiky 533 injectics SSSSSSSSSSSSSS&S Patent Application Publication Feb. 5, 2015 Sheet 24 of 26 US 2015/0037355A1 FIGURE 9 150 : as PBS serum(n=2) hGM-CSF594 serum(n=2) OO -- uv inactivated hCGM-CSF594 serum(n=2) eye mM-CSF594 serum(n=2) -8- JX-963 serum(n=2) ox- Reovirus serum(n=2) O s s s 8 8. S ° s” N Serum (%) FIGURE 10 150 \&s JX594 Serum -8. JX594mGM-CSF Serum -- Control: pre treatment serum’ m$x WR Serum 50 wax VSV Serum r:8tra VSV GM-CSF Serum Serum (%) Patent Application Publication Feb. 5, 2015 Sheet 25 of 26 US 2015/0037355A1 FIGURE 11 sys HSV serum(n=2) -- VSV GM-CSF serum (n=2) Serum (%) FIGURE 12 100 leuuougoK?IIqe?A% ULIITLIÐS &&&&&&&&& virus types Patent Application Publication Feb. 5, 2015 Sheet 26 of 26 US 2015/0037355A1 FIGURE 13 's s US 2015/0037355A1 Feb. 5, 2015 GENERATION OF ANTIBODIES TO TUMIOR reproducible delivery to distant tumors were limited, how ANTIGENS AND GENERATION OF TUMIOR ever. Systemic anti-cancer potency and blood-borne delivery SPECIFIC COMPLEMENT DEPENDENT to metastatic tumors therefore had to be improved. CYTOTOXCITY BY ADMINISTRATION OF 0006 Given both the potential and the limitations with ONCOLYTIC VACCNAVIRUS each of these three individual virus-based approaches, we asked whether it was possible to combine and optimize the RELATED APPLICATIONS best attributes of each into a single therapeutic agent. Tar 0001. The present application is the 35 USC 371 U.S. geted and armed oncolytic poxviruses have the potential to do national stage of international application no. PCT/US2012/ so. JX-594 is a 3'-generation oncolytic poxvirus therapeutic 020173, filed on Jan. 4, 2012 and claims the benefit of priority designed to have three complementary MOA including: 1) of U.S. Provisional Application No. 61/429,622, which was direct replication-mediated oncolysis, and 2) active cancer vaccination. JX-594 is a Wyeth vaccinia virus vaccine-de filed on Jan.
Load more

Recommended publications
  • The Emerging Therapeutic Potential of the Oncolytic Immunotherapeutic Pexa-Vec (JX-594)
    Oncolytic Virotherapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) Caroline J Breitbach1 Abstract: Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate John C Bell2,3 in and lyse cancer cells, thereby triggering antitumor immunity. Numerous oncolytic platforms Tae-Ho Hwang1 are currently in clinical development. Here we review preclinical and clinical experience with David H Kirn1 Pexa-Vec (pexastimogene devacirepvec, JX-594). Pexa-Vec is derived from a vaccinia vaccine James Burke1 strain that has been engineered to target cancer cells and express the therapeutic transgene granulocyte macrophage colony-stimulating factor (GM-CSF) in order to stimulate antitumor 1SillaJen Inc, Seoul, South Korea; immunity. Key to its ability to target metastatic disease is the evolution of unique vaccinia virus 2Department of Biochemistry, Microbiology and Immunology, characteristics that allow for effective systemic dissemination. Multiple mechanisms of action University of Ottawa, Ottawa, (MOA) for Pexa-Vec have been demonstrated in preclinical models and patients: 1) tumor cell ON, Canada; 3Centre for Cancer Therapeutics, Ottawa infection and lysis, 2) antitumor immune response induction, and 3) tumor vascular disruption. Hospital Research Institute, This review will summarize data on the Pexa-Vec MOA as well as provide an overview of the Ottawa, ON, Canada Pexa-Vec clinical development
    [Show full text]
  • Transgene Announces a Follow-On Investment in Jennerex, Inc
    Transgene Announces a Follow-on Investment in Jennerex, Inc. Strasbourg, France, May 28, 2013 — Transgene SA (Euronext Paris: TNG), a biopharmaceutical company that develops immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announces an additional $2.5 million investment in the equity capital of Jennerex, Inc. The investment was made in the context of a $21.6 million private placement of shares to existing shareholders of the Company. The proceeds will notably be used for the financing of ongoing clinical studies with Pexa-Vec (JX549/TG6006), developed in collaboration with Transgene. Pexa-Vec is an oncolytic immunotherapy in phase 1 and 2 clinical trials in various cancers, including advanced liver cancer (hepatocarcinoma). To date, the product has been injected to 250 patients in North America, Asia and Europe, with promising data in terms of survival, tumor response and tolerability. “Our follow-on investment in Jennerex, Inc. reflects our confidence in Pexa-Vec, which should start its first phase 3 trial in the first part of 2014” said Philippe Archinard, Chairman and CEO of Transgene. He added: “Transgene is one of the world leaders in viral-based immunotherapy. Oncolytic immunotherapy is therefore core to our strategy”. Transgene owns approximately 10% of Jennerex, Inc. About Pexa-Vec: Pexa-Vec (JX-594/TG6006, pexastimogene devacirepvec) was derived from vaccinia, which has been used for decades as a vaccine in healthy individuals, and was engineered to selectively target cancer cells. Pexa-Vec was also engineered to express GM-CSF, a white blood cell growth factor, which activates a systemic immune response to kill tumor cells throughout the body.
    [Show full text]
  • Micromanaging Oncolytic Viruses
    TOOLS significantly greater survival (p<0.001) than littermates that received wild-type CVA21, all of which developed hind-limb paralysis and required killing. The authors concluded that incorporation of tissue-specific miRNA targets into oncolytic viruses “might increase their therapeutic index Micromanaging without perturbing their antitumor activity.” While the Mayo researchers focused on limiting muscle toxicity, a paper in the Journal of Virology describes a strategy to eliminate liver oncolytic viruses toxicity associated with systemic delivery of oncolytic adenoviruses. By Tim Fulmer, Senior Writer In that paper, researchers at the University of Helsinki and the University of California, San Francisco, constructed a recombi- Oncolytic viruses have had limited success as cancer therapies, largely nant adenovirus that contained a target sequence for liver-specific because of the need to balance potent antitumor activity with off-tar- miRNA-122. get toxicity. Two research teams have now applied a microRNA-based For a model, the researchers chose a liver cell line that expresses high strategy that could restrict the replication of oncolytic viruses to tumors levels of miRNA-122. Infection of those cells with a recombinant adeno- without the need for alterations to the viral genome that can lead to an viral strain containing three copies of the miRNA-122 target sequence overly attenuated strain.1,2 inserted at a site adjacent to genes required for viral replication led to Oncolytic viruses are engineered to selectively target and replicate undetectable levels of adenoviral proteins. within tumor cells, triggering lysis and cell death. Selective targeting is “The papers potentially usher in a new era of oncolytic virus regu- usually achieved by mutating the viral genome lation,” said John Bell, CSO of oncolytic virus to lower the likelihood that the virus will target “The papers potentially company Jennerex Biotherapeutics Inc.
    [Show full text]
  • Douglas Grant Mcfadden PRESENT POSITION
    Jan 4, 2016 CURRICULUM VITAE NAME: Douglas Grant McFadden PRESENT POSITION: Professor Department of Molecular Genetics & Microbiology University of Florida, College of Medicine 1600 SW Archer Road, Room R4-295 P.O. Box 100266 Gainesville, FL 32610-0266 Tel: (352) 273-6852 Cell: (352) 672-2263 Fax: (352) 273-6849 Email: [email protected] Web: http://www.mgm.ufl.edu/faculty/GMcFadden.htm DATE AND PLACE December 2, 1949 OF BIRTH: St. Thomas, Ontario, Canada NATIONALITY: Canada, United States (Dual citizen) MARITAL STATUS: Married, three children DEGREES: B.Sc. (Honors Biochemistry) 1970 McGill University Ph.D. (Biochemistry) 1975 McGill University PROFESSIONAL EXPERIENCE: Summer Research, Pathology Department, Summer, 1969 Royal Victoria Hospital, Montreal, Quebec Doctoral Research, Biochemistry Department, 1970-1975 McGill University, Montreal, Quebec (Supervisor: Dr. D.T. Denhardt) Postdoctoral Research, Dept. of Microbiology and Immunology, 1976-1980 University of Western Ontario, London, Ontario (Supervisor: Dr. S. Dales) Assistant Professor, Biochemistry Department, University of Alberta 1981-1984 Associate Professor, Biochemistry Department, University of Alberta 1984-1988 Tenure awarded (University of Alberta) 1986 Sabbatical Research, Dept. of Microbiology and Molecular Biology, 1987-1988 Harvard University (Host: Dr. M. Greenberg) Professor, Biochemistry Department, University of Alberta 1989-1996 Director, Group on the Molecular Mechanisms of Growth Control, U Alberta 1991-1996 Professor, Dept. of Microbiology and Immunology, 1997-2006 University of Western Ontario, London, Ontario Co-director, Biotherapeutics Group, Robarts Research Institute, London, Ontario 2001-2006 Member, UF Shands Cancer Center, Gainesville, Florida 2006-present Member, UF McKnight Brain Institute, Gainesville, Florida 2006-present Collaborative Member, Chem. Biol. & Mol. Med., Moffit Cancer Center, Tampa 2009-present Professor, Dept.
    [Show full text]
  • Transgene Announces That Clinical Data with Pexa-Vec Will Be Presented at the 2013 American Society of Clinical Oncology Annual Meeting
    Transgene Announces that Clinical Data with Pexa-Vec will be Presented at the 2013 American Society of Clinical Oncology Annual Meeting Strasbourg, France, May 15, 2013 — Transgene SA (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, today announced that data relating to Pexa-Vec (JX-594; pexastimogene devacirepvec), an oncolytic virus developed to treat cancers, was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, May 31 to June 4, 2013. Details of the presentations follow: - Abstract #3608, Poster: Phase 1b Dose-Escalation Study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, Administered by Intravenous (IV) Infusions in Patients with Metastatic Colorectal Carcinoma (mCRC). June 2, 2013 8:00 am, Location S Hall A2. - Abstract #4122, Poster: Phase 2 Trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, followed by Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC). June 2, 2013 8:00 am, Location S Hall A2. - Abstract #TPS4161 (Trials in Progress), Poster: Phase 2b Randomized Trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a Targeted Oncolytic Vaccinia Virus, plus Best Supportive Care (BSC) Versus BSC Alone in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment (TRAVERSE). June 2, 2013 8:00 am, Location S Hall A2. Last week, Pexa-Vec was granted the Orphan Drug Status to treat hepatocellular carcinoma by the FDA, a status the oncolytic virus already has in Europe.
    [Show full text]
  • Oncolytic Virotherapy As Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
    REVIEW ARTICLE published: 01 May 2014 doi: 10.3389/fonc.2014.00092 Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1 1 † 1† 1 2 1 Markus Moehler * , Katrin Goepfert , Bernd Heinrich , Caroline J. Breitbach , Maike Delic , 1 3 Peter Robert Galle and Jean Rommelaere 1 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz, Mainz, Germany 2 Jennerex Biotherapeutics, Inc., San Francisco, CA, USA 3 Division of Tumor Virology, German Cancer Research Center (DKFZ), Heidelberg, Germany Edited by: Human tumors develop multiple strategies to evade recognition and efficient suppression Philippe Fournier, DKFZ, Germany by the immune system. Therefore, a variety of immunotherapeutic strategies have been Reviewed by: developed to reactivate and reorganize the human immune system. The recent develop- Valery Grdzelishvili, University of North Carolina at Charlotte, USA ment of new antibodies against immune check points may help to overcome the immune Volker Schirrmacher, DKFZ, Germany silencing induced by human tumors. Some of these antibodies have already been approved Yong Lu, Cleveland Clinic Foundation, for treatment of various solid tumor entities. Interestingly, targeting antibodies may be USA combined with standard chemotherapy or radiation protocols. Furthermore, recent evi- William L. Redmond, Earle A. Chiles dence indicates that intratumoral or intravenous injections of replicative oncolytic viruses Research Institute, USA such as herpes simplex-, pox-, parvo-, or adenoviruses may also reactivate the human *Correspondence: Markus Moehler, 1st Department of immune system. By generating tumor cell lysates in situ, oncolytic viruses overcome cel- Internal Medicine, University Medical lular tumor resistance mechanisms and induce immunogenic tumor cell death resulting Center of the Johannes Gutenberg, in the recognition of newly released tumor antigens.
    [Show full text]
  • Beijing Shenogen Pharma Group Limited and Lee's Pharmaceutical
    FOR IMMEDIATE RELEASE Beijing Shenogen Pharma Group Limited and Lee’s Pharmaceutical (HK) Limited Announce Development and Commercialization Collaboration Agreement for Pexa-Vec and Icaritin in China (Beijing-Hong Kong – August 24, 2016) - Lee’s Pharmaceutical (HK) Ltd., a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”, SEHK Stock Code: 950) and Beijing Shenogen Pharma Group Ltd. (“Shenogen”) entered a collaboration agreement to jointly develop and commercialize in China a combination product that is composed of their respective clinical compounds, Pexa-Vec and icaritin, for treatment of late stage cancers. Lee’s Pharm is currently developing Pexa-Vec (Pexastimogene Devacirepvec, JX-594), an oncolytic virus, for treatment of late stage cancers including hepatocellular carcinoma (HCC). Shenogen is currently developing icaritin, a small molecule for treatment of late stage HCC. Icaritin, has demonstrated synergistic effects with oncolytic virus in animal models. Both Lee’s Pharm and Shenogen believe by combining these two compounds in treating late stage cancer patients there will be an enhanced efficacy than either product alone. “Lee’s Pharm is looking forward to collaborating with Shenogen” Dr. Benjamin Li, CEO of Lee’s Pharm, said. “to bring more benefits to cancer patients especially HCC patients in China”. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd, further expressed his enthusiasm and confidence about collaborating with Lee’s Pharm. About Pexa-Vec: Pexastimogene Devacirepvec (Pexa-Vec, JX-594) is an oncolytic therapeutic vaccinia virus that is designed to selectively replicate in and destroy cancer cells, while at the same time stimulating a systemic anti-tumoral immune response through the expression of its transgene, human granulocyte-macrophage colony stimulating factor (hGM-CSF) in the context of tumor lysis.
    [Show full text]
  • Progress in Clinical Oncolytic Virus-Based Therapy for Hepatocellular Carcinoma
    This is a repository copy of Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/87572/ Version: Accepted Version Article: Jebar, AH, Errington-Mais, F, Vile, RG et al. (3 more authors) (2015) Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology, 96 (7). 1533 - 1550. ISSN 0022-1317 https://doi.org/10.1099/vir.0.000098 Reuse Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Journal of General Virology Progress in Clinical Oncolytic Virus-based Therapy for Hepatocellular Carcinoma --Manuscript Draft-- Manuscript Number: JGV-D-14-00137R1 Full Title: Progress in
    [Show full text]
  • FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical Presents
    ______________________________________________________________________________________ FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer —Median Survival of 13.8 Months (high dose) vs. 6.7 Months (low dose)— San Francisco, California, November 30, 2011--Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented final data from a randomized dose-ranging Phase 2 clinical trial of JX-594 in patients with advanced liver cancer showing a statistically significant benefit in overall survival for the high JX-594 dose group versus the low dose group. The final data from the HEP007 trial demonstrated that the risk of death for patients who received JX-594 at the high dose was markedly reduced (by nearly 60 percent; hazard ratio = 0.41) when compared to patients randomized to a low dose control (one-tenth of the high dose). The median overall survival for high and low dose groups was 13.8 months versus 6.7 months, respectively (p = 0.029 for superiority of the high dose). The percent of patients alive at one year was 66 percent versus 23 percent in high- and low-dose groups, respectively (Kaplan-Meier estimate). JX-594 was well-tolerated with patients experiencing transient flu-like symptoms that generally resolved within 24 hours. This clinical trial, HEP007, was led by Jennerex in North America and by Green Cross in South Korea and enrolled 30 patients at sites in the United States, Canada and South Korea.
    [Show full text]
  • FOR IMMEDIATE RELEASE Jennerex and Lee's Pharmaceutical Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594
    ______________________________________________________________________________________ FOR IMMEDIATE RELEASE Jennerex and Lee’s Pharmaceutical Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecanin Patients with Metastatic Colorectal Cancer San Francisco, California and Hong Kong, March 21, 2012--Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab. The two-arm, dose-escalation study will evaluate JX-594 as a monotherapy and in combination with irinotecan. The multicenter study will be conducted in the United States, Canada and Europe and is designed to enroll up to 42 patients. Patients will be enrolled in one of two treatment groups—one treatment group will receive JX-594 as a monotherapy and one treatment group will receive JX-594 in combination with irinotecan. Patients in both groups will receive fiveweekly intravenous infusions of JX-594 at one of two escalating dose levels followed by up to threeoptional intratumoral injections or JX-594 into metastases to the liver, if any. The combination group will receive concomitant administrations of irinotecan. Once the maximum tolerated dose is determined for each treatment group, additional patients will be enrolled at that dose level. The endpoints of the trial include safety, dose optimization, and tumor responses as measured by RECIST and Choi criteria.
    [Show full text]
  • Jennerex and Lee's Pharmaceutical Announce Completion Of
    FOR IMMEDIATE RELEASE Media Contacts: Jennerex Lee’s Pharmaceutical Kelly France, BrewLife Vivian Fung 415-946-1076 852-2314-1282 [email protected] [email protected] Jennerex and Lee’s Pharmaceutical Announce Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer San Francisco, Calif. – May 22, 2013 — Jennerex Biotherapeutics, Inc., a private, clinical- stage biotechnology company focused on the development and commercialization of best-in- class targeted oncolytic immunotherapies for solid tumors, today announced that it completed enrollment of 120 patients in the TRAVERSE study, a global randomized Phase 2b clinical trial evaluating the efficacy and safety of Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of advanced primary liver cancer (hepatocellular carcinoma, HCC) in patients who failed prior therapy with sorafenib (Nexavar®). Pexa-Vec, Jennerex’s lead product candidate, is an investigational oncolytic immunotherapy designed to 1) rapidly de-bulk tumors via tumor cell lysis, 2) induce a systemic anti-tumor immune response, and 3) selectively target tumor vasculature resulting in a rapid reduction in tumor blood flow. "We are pleased to have completed enrollment in TRAVERSE, the largest study to date of Pexa-Vec, ahead of schedule,” said Laurent Fischer, M.D., president and chief executive officer of Jennerex. “We would like to thank investigators and patients who participated in the study. We believe that physician and patient interest in this trial validates our novel approach to treating HCC and underscores the need for new treatment options for liver cancer, the third most deadly cancer.” The primary objective of TRAVERSE is to determine the overall survival for patients receiving Pexa-Vec with best supportive care, compared to those receiving best supportive care alone.
    [Show full text]
  • Transgene Announces Plans for a Phase 1B/2 Trial with Pexa-Vec in Advanced Solid Tumors
    Transgene Announces Plans for a Phase 1b/2 Trial with Pexa-Vec in Advanced Solid Tumors While the Company is Finalizing Full Development Plan for Pexa-Vec with Partners Strasbourg, France, February 25, 2014 - Transgene SA (NYSE-Euronext: TNG) today announced plans for a Phase 1b/2 trial with Pexa-Vec that is to be funded by the Institut National du Cancer (INCa). This trial will be part of an INCa-funded program called CLIP², that is facilitating patient access to innovative treatments and promoting global exchanges in cutting edge research that involve academic-initiated research and novel therapies being developed by biotechnology and pharmaceutical companies. “We are pleased with the interest shown to further develop Pexa-Vec by INCa. It is noteworthy that Transgene will be one of the first biotechnology companies to have a trial funded by INCa” said Philippe Archinard, Chairman and Chief Executive Officer of Transgene. “This trial complements the development plan we are finalizing with our partners, which is expected to include a global Phase 3 trial in advanced liver cancer, as well as exploratory and supportive Phase 2 studies in a variety of cancer types and with various other therapies. We look forward to providing soon a more comprehensive update on our plans for Pexa-Vec once our partner SillaJen’s acquisition of Jennerex has closed.” The Phase 1b/2 trial will evaluate Pexa-Vec in combination with metronomic cyclophosphamide, a drug used in combination with other therapies to treat a wide variety of cancers. The trial, expected to be initiated later in 2014, is sponsored by Bergonié Institute (Bordeaux, France).
    [Show full text]